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Platinum drugs play an important role in the treatment of ovarian
(McGuire and Ozols, 1998) and testicular (Einhorn, 1997) cancer
but their clinical application can be limited by cumulative damage
to the peripheral nervous system (McKeage, 1995). Some plat-
inum derivatives cause frequent or severe symptoms in patients
(Gerritsen van der Hoop et al, 1990; Schilder et al, 1994;
Machover et al, 1996; O’Rourke et al, 1998), such as numbness or
pins and needles in the hands and feet, incoordination and deaf-
ness, while other analogues are associated with infrequent or mild
neurotoxicity (Canetta et al, 1985; Judson et al, 1997). We have
been interested in the mechanism of platinum-induced neuro-
toxicity and sought to understand why these effects vary between
different analogues.
The mechanism of neurotoxicity induced by platinum drugs has
been proposed to involve the accumulation of platinum within the
peripheral nervous system (Gregg et al, 1992). Evidence in
support of this mechanism includes: (1) that exposure to other
heavy metals, e.g. lead and mercury, is associated with similar
cumulative neurotoxicity and heavy metal accumulation in
nervous tissue (Goyer, 1996); (2) that the severity of neurotoxicity
associated with cisplatin in patients has been shown to correlate
with the concentration of platinum in peripheral nerves (Gregg et
al, 1992); and (3) that differences in platinum concentrations
between the dorsal root ganglia (DRG) and anterior horn of the
spinal cord correlates with the selective toxicity of platinum drugs
to peripheral sensory neurons and the sparing of motor neurons
from toxicity (Thompson et al, 1984; Gregg et al, 1992).
We hypothesized that the differential neurotoxicity of platinum
derivatives may be due to differences in their partitioning into the
lipid-rich environment of the nervous system. To test this hypoth-
esis, we measured the hydrophobicity of a series of eight platinum
drugs, and in an extension to our previous studies (McKeage et al,
1994; Screnci et al, 1997), we measured the potency of a series of
compounds for altering sensory nerve conduction velocity
(SNCV) in Wistar rats treated on a twice per week dosing schedule
at the maximum tolerated dose (MTD). We measured the concen-
trations of platinum in various tissues from the nervous system of
rats treated with different platinum derivatives using an induc-
tively coupled plasma mass spectrometry (ICP-MS) technique
developed in our laboratory (Screnci et al, 1998) and the reactivity
of the compounds to plasma proteins. We correlated the experi-
mental parameters and determined whether changes in SNCV in
rats predicted neurotoxicity in patients.
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Summary Previous work has shown platinum drugs to differ in their effects on the peripheral nervous system. To test whether their differential
toxicity was due to differences in their partitioning into the peripheral nervous system, we correlated the hydrophobicity, reactivity, tissue
accumulation and neurotoxicity of a series of eight platinum analogues. Neurotoxicity was detected by measuring sensory nerve conduction
velocity (SNCV) in Wistar rats treated twice per week at the maximum tolerated dose. Tissue platinum concentrations were measured by
inductively coupled plasma mass spectrometry. Hydrophobicity (log P) was measured using an octanol-aqueous shake-flask method. The
half-life of platinum drug binding to plasma proteins in vitro was determined. The cumulative dose causing altered SNCV ranged from 15 to 
> 2050 mmol kg–1. Ranking of the compounds by their neurotoxic potency in rats (oxaliplatin > R,R-(DACH)PtC4 > ormaplatin > S,S-
(DACH)PtCl4 > S,S-(DACH)Pt oxalato > cisplatin > carboplatin > JM216) correlated with the frequency of neurotoxicity in patients (r > 0.99; 
P < 0.05). Ranking the compounds by their peripheral nerve accumulation was cisplatin > carboplatin > oxaliplatin > R,R-(DACH)PtCl4 » S,S-
(DACH)PtCl4 and did not correlate with neurotoxicity. Log P ranged from – 2.53 to –0.16 but did not correlate with neurotoxicity. Log 
P correlated inversely with platinum accumulation in dorsal root ganglia (r2 = 0.99; P = 0.04), sural nerve (r2 = 0.85; P = 0.025), sciatic nerve
(r2 = 0.98; P = 0.0012), spinal cord (r2 = 0.97, P = 0.018) and brain (r2 = 0.98, P = 0.001). Reactivity correlated with neurotoxicity potency in
rats (r2 = 0.89, P = 0.0005) and with the frequency of neurotoxicity in patients (r2 = 0.99, P = 0.0002). The hydrophilicity of platinum drugs
correlates with platinum sequestration in the peripheral nervous system but not with neurotoxicity. Differences in the reactivity of platinum
complexes accounts for some of the variation in their neurotoxicity. © 2000 Cancer Research Campaign
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Drugs (Table 1, Figure 1)
Cisplatin and carboplatin were purchased from Sigma (St Louis,
MO, USA). The R,R- and S,S-enantiomers of ormaplatin
((DACH)PtCl4) and oxaliplatin ((DACH)Pt(oxalato)) were synthe-
sized as outlined previously (Screnci et al, 1997). JM216 was
kindly provided by the Johnson Matthey Technology Centre
(Reading, UK). The racemic mixture of ormaplatin was kindly
supplied by the National Cancer Institute (Bethesda, MD, USA).
Hydrophobicity measurements
The hydrophobicity (log P) of the series of compounds was deter-
mined using a shake-flask method (Albert, 1979). Aqueous (0.9%
(w/v) sodium chloride (NaCl) and organic (n-octanol) phases were
saturated for 1 week. Drugs were dissolved at a final concentration
of 300 mM in the aqueous phase. An equal volume of saturated n-
octanol was added and the solutions mixed for 30 min (45 rpm).
Samples were centrifuged (1500 g, 10 min) and the platinum
content of the organic and aqueous phases determined by ICP-MS.
The log of the ratio of platinum concentrations in the organic and
aqueous phases were calculated to determine log P.
The hydrophobicity of the series of compounds was also
measured using a high-performance liquid chromatography (HPLC)
method adapted from a previously reported technique (Braumann,
1986). The HPLC system consisted of a Hewlett Packard HP 1100
HPLC, a Prodigy C8 5 mm column (Phenomenex, Auckland, New
Zealand) and a mobile phase consisting of 100% Milli-Q water at a
flow rate of 1 ml min–1. Methanol was added to the mobile phase for
studies of JM216. The HPLC eluent was introduced directly into a
Hewlett Packard 4500 ICP-MS. The ICP-MS conditions for
detecting platinum were as outlined previously (Screnci et al, 1998).
Compounds were dissolved in 0.9% NaCl at a concentration of
50 mM and injected onto the column (20 ml). Hydrophobicity was
measured by determining the capacity factor for each compound
when the actual or projected mobile phase composition was
100% water, using the formula; capacity factor = [void volume –
retention volume]/void volume. The void volume was deter-
mined by detecting the appearance of Cl2 in the HPLC eluent by
ICP-MS at mass 35. The retention volume was determined by
detecting the presence of platinum in the HPLC eluent by ICP-
MS at mass 195.
Reactivity measurement
Plasma from control female Wistar rats was incubated at 37°C
with the platinum compounds at a final concentration of 1 mM.
Aliquots of plasma (200 ml) were taken at designated times, added
to an equal volume of ice-cold methanol and placed at –20°C
overnight. Samples were spun at 38 416 g for 15 min, an aliquot 
of supernatant was diluted (tenfold) with 1% nitric acid before
analysis by ICP-MS. The initial half-life of binding to plasma
proteins was determined by curve fitting (one-phase exponential
decay) using Graph Pad Prism (GraphPad Software, CA, USA).
Animals and treatment
Age-matched inbred female Wistar rats were used. Animals were
allowed to acclimatize for 2 weeks before the start of the
experiment. The animals were 10 weeks old and weighed 210–
240 g at the start of experiment. Platinum compounds (except
JM216) were dissolved in sterile 0.9% (w/v) NaCl (Baxter
Healthcare, New Zealand) by vortex mixing and sonication at an
injection volume of 10 ml kg–1. The platinum compounds (except
JM216) were given by intraperitoneal injection on a twice per
week dosing schedule at intervals of 3–4 days and the treatment
was repeated weekly for a total of 8 weeks. JM216 was made up as
a suspension in arachis oil and given by oral gavage (McKeage et
al, 1994). Animals were weighed twice a week and checked for
signs of toxicity daily. Animals showing signs of distress were
immediately and painlessly killed. Animals had continuous access
to food and water. The project was approved by The University of
Auckland Animal Ethics Committee.
Neurotoxicity assessment
SNCV was calculated from recordings of evoked H-plantar
responses before treatment and once a week during treatment as
previously described (McKeage et al, 1994) 72 h after platinum
drug administration. Hypnorm (fluanisone 10 mg ml–1, fentanyl
citrate 0.3 mg ml–1, Jansen Pharmaceuticals, Sydney, Australia)
diluted 1:1 with sterile water was given by intramuscular injection
to provide light anaesthesia. Responses were evoked by stimu-
lating the sciatic nerve at the sciatic notch and the tibial nerve at
the ankle of the left hind limb using percutaneous needle elec-
trodes. H- and M-waves were recorded using a pair of superficial
silver-silver chloride electrodes applied to the sole and dorsum 
of the hind paw. H- response-related SNCV was calculated by
dividing the distance between the stimulation sites at the sciatic
notch and ankle by the difference in H-response latency after
stimulation at the ankle and sciatic notch. Differences between the
means of the control and treatment groups were assessed using a 
t-test. A P-value of less than 0.05 was regarded as significant.
Neurotoxicity was considered present when there was a statisti-
cally significant difference in mean SNCV between the control
and treatment groups.
Tissue platinum determinations
Animals were treated with cisplatin (3.33 mmol kg–1), carboplatin
(21.6 mmol kg–1), oxaliplatin (2.5 mmol kg–1) and the R,R-
(2.6 mmol kg–1) and S,S- (2.6 mmol kg–1) enantiomers of
ormaplatin repeated twice per week for up to 8 weeks at the MTD
(McKeage et al, 1994; Screnci et al, 1997). Platinum compounds
were prepared and given as outlined above.
Three animals were killed by exsanguination under terminal
anaesthesia using sodium pentobarbitone (300 mg kg–1;
Chemstock Animal Health Ltd, Christchurch, New Zealand) at 7,
14, 21, 28, 35, 42, 49 and 56 days for the collection of tissues for
platinum analysis. Animals were sacrificed 3 days after the last
platinum dose. Blood was collected from the axillary artery into
heparinized tubes (Becton and Dickinson, NJ, USA) and plasma
was prepared by centrifugation at 3000 g for 10 min at 4°C. The
plasma samples were stored at –20°C until analysis.
Samples of brain, DRG, spinal cord, sural nerve and sciatic
nerve were collected. Tissues were washed with Milli-Q water,
blotted dry and placed into pre-weighted 15-ml screw cap tubes.
Tissues were prepared for ICP-MS analysis as outlined previously
(Screnci et al, 1998). Briefly, tissues were left to stand overnight
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The following day, tissues were digested for 2 h at 90°C in a sand-
filled electric frying pan positioned in a fume hood. The solubi-
lized tissues were made to volume in 10-ml volumetric flasks
using Milli-Q water and introduced into the ICP-MS. Platinum
analysis was undertaken as outlined previously (Screnci et al,
1998) using a HP 4500 (Hewlett Packard) ICP-MS with a nickel
sampling cone, V groove nebulizer and a Scott double-pass spray
chamber. Platinum was read at 195 amu with a dwell time of 
100 ms and a replicate time of 6000 ms. An index of platinum
accumulation was derived by calculating the area under the plat-
inum concentration versus time curve (platinum concentration-
time product) from days 0–56 using the trapezoid rule and Graph
Pad Prism (GraphPad Software Inc., CA, USA).
Blood and plasma platinum determinations were measured by
ICP-MS. At the beginning and the end of each run, a matrix-free
platinum standard curve was run ranging from 0 to 1000 ng ml–1.
Platinum standards were made up by diluting a 1000 mg ml–1 plat-
inum standard in 10% hydrochloric acid (Spex Certi Prep, USA).
Plasma (100 ml) was diluted with 2.4 ml of lysis buffer (0.1%
NH4EDTA (Aldrich, Milwalkee, IL, USA), 0.1% Triton X-100
(Serva, Heidelberg, Germany) in 2.5% ammonium hydroxide
(BDH Chemicals, Poole, UK)) and introduced into the ICP-MS for
analysis.
Statistical analysis
The significance of relationships between experimental parame-
ters was assessed using linear regression and rank correlation. A
two-sided P-value of < 0.05 was regarded as statistically signifi-
cant. Confidence intervals for the incidence of neurotoxicity in
patients were calculated using Graph Pad StatMate (GraphPad
Software, CA, USA).
RESULTS
The peripheral neurotoxicity of cisplatin, carboplatin and racemic
ormaplatin was assessed in female Wistar rats treated on a twice
per week dosing schedule at the MTD. Data were combined with
previous results for JM216, oxaliplatin, its S,S-enantiomer and the
R,R- and S,S-enantiomers of ormaplatin obtained using the same
experimental protocol (McKeage et al, 1994; Screnci et al, 1997).
The cumulative dose required to induce altered SNCV in the
Wistar rat model ranged from 15 to > 2050 mmol kg–1 (Table 1).
The number of weeks of treatment required for the development of
altered SNCV ranged from 3 to > 20.5 weeks (Table 1).
To provide a relationship between their effects in the Wistar rat
model and in patients, clinical toxicity data for cisplatin, carbo-
platin, oxaliplatin, ormaplatin and JM216 were obtained from the
literature (Table 1) (Canetta et al, 1985; Gerritsen van der Hoop et
al, 1990; Schilder et al, 1994; Machover et al, 1996; Judson et al,
1997; O’Rourke et al, 1998). The percentage of patients experi-
encing neurotoxicity during treatment with these platinum drugs
ranged from 5.6 to 97%. Ranking of the compounds according to
the incidence of neurotoxicity in patients correlated with their
ranking by the dose potency for altering SNCV in rats (rank corre-
lation coefficient < –0.99; P < 0.05) and by the time required for
the development of neurotoxicity in rats (rank correlation coeffi-
cient < –0.99; P < 0.05).
To measure tissue concentrations of platinum, rats were treated
with cisplatin, carboplatin, oxaliplatin (R,R-(DACH)Pt(oxalato))
and the enantiomers of ormaplatin (R,R-(DACH)PtCl4 and S,S-
(DACH)PtCl4) twice per week at the MTD. Brain, spinal cord,
DRG, sural nerve, sciatic nerve, whole blood and plasma were
analysed weekly for platinum content by ICP-MS. There was a
time-dependent increase in tissue associated platinum for all
drugs. The data for the R,R- and S,S-enantiomers of ormaplatin are
shown in Figure 2. Platinum concentrations in brain and spinal
cord were approximately tenfold lower than in DRG, sural nerve
and sciatic nerve. Area under the platinum concentration versus
time courses from days 0 to 56 (platinum concentration-time prod-
ucts) were calculated as an index of platinum accumulation (Table
2). Ranking the compounds according to their tissue accumulation
was similar for all tissues; cisplatin > carboplatin > oxaliplatin >
R,R-(DACH)PtCl4 » S,S-(DACH)PtCl4. However, ranking the
compounds according to their plasma platinum concentration-time
products was; R,R-(DACH)PtCl4 » S,S-(DACH)PtCl4 > cisplatin >
carboplatin > oxaliplatin. Whole blood platinum concentrations
were similar for all drugs.
To provide a relationship between platinum accumulation and
neurotoxicity, concentration-time products in tissues, blood and
plasma (Table 2) were related to the neurotoxicity of cisplatin,
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Table 1 Ranking of platinum compounds by their peripheral neurotoxicity in female Wistar rats and patients
Compound Female Wistar rat Patients
Neurotoxic Time to Incidence of Reference
potency development neurotoxicity
(mmol kg–1)a of altered in patients
SNCV (weeks)b % (95% CI)
Oxaliplatinc 15.0 3.0 97 (92–99) Machover et al, 1996
R,R-(DACH)PtCl4
d 17.6 4.0 –
Ormaplatine 26.0 6.0 87 (47–100) Schilder et al, 1994; O’Rourke et al, 1998
S,S-(DACH)PtCl4
f 30.8 7.0 –
S,S-(DACH)Pt-oxalatog 35.0 7.0 –
Cisplatin 46.7 7.0 47 (41–53) Van Der Hoop et al, 1990
Carboplatin 302.0 8.0 5.8 (3.8–8.5) Canetta et al, 1985
JM216 > 2050.0 > 20.5 5.6 (0–27) Judson et al, 1997
aCumulative dose causing altered SNCV in female Wistar rats during repeated treatment with a twice per week dosing schedule at the MTD.
bThe number of weeks of treatment on a twice per week dosing schedule at the MTD required for the development of altered SNCV. cR,R-
(DACH)Pt(oxalato). dR,R-enantiomer of ormaplatin. eRacemic mixture of R,R-(DACH)PtCl4 and S,S-(DACH)PtCl4. fS,S-enantiomer of ormaplatin.
g S,S-enantiomer of oxaliplatin.carboplatin, oxaliplatin and the R,R- and S,S-enantiomers of
ormaplatin (Table 1). There was no correlation between neurotoxic
potency and platinum concentration-time products in DRG (r2 =
0.16; P = 0.57), sural nerve (r2 = 0.01; P = 0.86), sciatic nerve 
(r2 = 0.18; P = 0.48), brain (r2 = 0.19; P = 0.46), spinal cord (r2 =
0.36; P = 0.28), blood (r2 = 0.14, P = 0.54) or plasma (r2 = 0.23, P
= 0.41). At the MTD, cisplatin and carboplatin showed greater
tissue concentrations of platinum (Table 2) but less neurotoxicity
(Table 1) than oxaliplatin and the isomers of ormaplatin. Animals
treated with the R,R- and S,S-enantiomers of ormaplatin showed
similar tissue concentrations of platinum (Figure 2) but a 2.6-fold
difference in neurotoxicity (Table 1).
Hydrophobicity of the compounds was measured using an
octanol–saline partitioning method (Albert, 1979). Log P values
ranged from –2.53 to –0.16 and are shown in Table 3. In attempt to
improve the precision of these estimates, another hydrophobicity
parameter (log kw) was measured by a reverse-phase HPLC tech-
nique adapted from Braumann (1986). Log kw correlated weakly
with log P (r2 = 0.77, P = 0.004). Hydrophobicity ranking of the
compounds differed when log kw was used as a measure of
hydrophobicity instead of log P (Table 3). Correlations between
hydrophobicity and tissue platinum accumulation were stronger
with log P (Figure 3) than log kw.
To determine whether hydrophobicity correlated with neurotox-
icity, the relationship between log P and neurotoxicity in rats and
patients was assessed by linear regression. Log P did not correlate
with neurotoxic potency in rats (r2 = 0.40, P = 0.09), the time to
development of neurotoxicity in rats (r2 = 0.34, P = 0.13) or with
the incidence of neurotoxicity in patients (r2 = 0.01, P = 0.87). To
determine whether the accumulation of platinum was related to
hydrophobicity, log P was correlated with platinum concentration-
time products in neurological tissues, blood and plasma (Figure 3).
Highly significant inverse correlations were found between log P
and platinum concentration-time products in DRG (r2 = 0.99; P =
0.004), sural nerve (r2 = 0.85; P = 0.025), sciatic nerve (r2 = 0.98;
P = 0.0012), brain (r2 = 0.98, P = 0.0011) and spinal cord (r2 =
0.97; P = 0.0018). Log P did not correlate with platinum concen-
tration-time products in blood (r2 = 0.08; P = 0.64) or plasma (r2 =
0.41; P = 0.25).
The reactivity of cisplatin, oxaliplatin, its S,S-enantiomer,
ormaplatin, its R,R- and S,S-enantiomers, and JM216 was deter-
mined by measuring their half-lives of binding to plasma proteins
in vitro (Table 4). Data were combined with literature values for
carboplatin (van der Vijgh and Klein, 1986). The half-life of
binding to plasma proteins ranged from 0.78 to 65 h. Reactivity of
the platinum compounds correlated with their neurotoxicity
potency in rats (r2 = 0.89; P = 0.0005), with the time to develop-
ment of neurotoxicity in rats (r2 = 0.55; P = 0.036) and with the
incidence of neurotoxicity associated with their use in patients (r2
= 0.99; P = 0.0002). There was no correlation between reactivity
and platinum concentration-time products or between reactivity
and hydrophobicity.
DISCUSSION
In our previous work, platinum drugs had showed differing effects
on the peripheral nervous system in a Wistar rat model (McKeage
et al, 1994; Screnci et al, 1997). We now report an attempt to corre-
late their differential neurotoxicity with their hydrophobicity and
tissue accumulation. We found no correlation between the concen-
tration of platinum in the peripheral nervous system and the neuro-
toxicity of a series of platinum derivatives in a Wistar rat model.
We showed that cisplatin and carboplatin were associated with
higher concentrations of platinum in peripheral nerves but less
neurotoxicity than oxaliplatin and the enantiomers of ormaplatin,
at the MTD in rats. Furthermore, the enantiomers of ormaplatin
had similar tissue concentrations of platinum but a 2.6-fold differ-
ence in neurotoxicity. Another group (Holmes et al, 1998) recently
reported their studies on the comparative toxicity of cisplatin,
oxaliplatin and ormaplatin to DRG in Wistar rats. They also found
cisplatin to be associated with higher concentrations of platinum in
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Figure 1 Chemical structures of platinum complexes
Table 2 Tissue, blood and plasma platinum concentration-time products (mg g–1 day–1 or mg ml–1 day–1) from days 0 to 56
associated with various platinum drugs
Cisplatin Carboplatin Oxaliplatin R,R-(DACH)PtCl4 S,S-(DACH)PtCl4
Dorsal root ganglia 32.4 23.1 13.1 8.28 8.00
Sural nerve 41.9 16.6 8.80 5.14 7.28
Sciatic nerve 24.9 17.8 9.65 4.38 4.83
Brain 3.98 2.93 1.43 0.94 0.97
Spinal cord 5.52 4.96 1.72 1.08 1.11
Blood 131.0 99.9 118 106 97.3
Plasma 10.6 6.17 5.45 22.7 22.4970 D Screnci et al
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DRG than ormaplatin and oxaliplatin, but that the ranking of the
compounds according to DRG morphometric change was
ormaplatin  ³ oxaliplatin > cisplatin or ormaplatin > cisplatin ³
oxaliplatin. Taken together, these findings suggest that the periph-
eral nerve damage caused by platinum drugs involves mechanisms
other than the accumulation of elemental platinum within the
tissues of peripheral nervous system.
Other workers have found significant relationships between
cisplatin dose, the severity of neurotoxicity and the concentration
of platinum in the peripheral nervous system in patients treated
with cisplatin (Gregg et al, 1992). Patients receiving high cumula-
tive doses of cisplatin experienced greater toxicity and higher
tissue concentrations of platinum in this study. Other platinum
drugs are likely to show similar relationships between dose, tissue
Table 3 Hydrophobicity parameters
Compounds Log Pf Log kw
g
Cisplatin –2.53 ± 0.28 –1.00, 0.97
Carboplatin –2.3 ± 0.10 0.20
Oxaliplatind –1.65 ± 0.21 0.44, 0.45
S,S-(DACH)Pt oxalatoe –1.59 ± 0.21 0.44, 0.45
R,R-(DACH)PtCl4
b –1.18 ± 0.15 0.40, 0.42
Ormaplatina –1.17 ± 0.13 0.40, 0.41
S,S-(DACH)PtCl4
c –1.03 ± 0.14 0.41, 0.41
JM216 –0.16 ± 0.16 2.27, 2.40
aRacemic mixture of R,R-(DACH)PtCl4 and S,S-(DACH)PtCl4. bR,R-
enantiomer of ormaplatin. cS,S-enantiomer of ormaplatin. dR,R-(DACH)Pt
oxalato. eS,S-enantiomer of oxaliplatin. fMean ± standard error (n = 5).
gDeterminants from independent experiments.
Table 4 Reactivity of platinum complexes measured by the half-life of
binding to plasma proteins in vitro
Compounds t (h)a
S,S-(DACH)PtCl4
b 0.78±0.084
R,R-(DACH)PtCl4
c 0.97±0.07
Ormaplatind 1.01±0.15
Oxaliplatine 1.19±0.10
S,S-(DACH)Pt oxalatof 1.21±0.13
Cisplatin 3.43±0.58
Carboplating 48.6
JM216 65±27
a±Standard error. bS,S-enantiomer of ormaplatin. cR,R-enantiomer of
ormaplatin. dRacemic mixture of R,R-(DACH)PtCl4 and S,S-(DACH)PtCl4.
eR,R-(DACH)Pt oxalato. fS,S-enantiomer of oxaliplatin. gData from van der
Vijgh and Klein, 1986.
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concentrations of platinum and neurotoxicity. However, they will
differ in the tissue levels of platinum associated with toxicity
because their neurotoxicity is not due to the accumulation of
elemental platinum in nerves but some intrinsic property of the
platinum complex or its biotransformation product(s).
The assay we used to measure tissue platinum (Screnci et al,
1998) did not distinguish between different platinum-containing
species or adducts. Platinum drugs are known to form different
species in biological systems and to bind to DNA and sulphydryl
groups of proteins forming various adducts (Borch, 1987). Their
differential neurotoxicity could possibly be due to the formation 
of different platinum-containing species or adducts within the
peripheral nervous system. These differences would not have been
detected by the ICP-MS assay because it determined total plat-
inum content and did not differentiate between different platinum-
containing species or adducts.
To provide a relationship between hydrophobicity and neuro-
toxicity, we attempted to measure the octanol–saline partition
coefficients (log P) of the compounds using a shake-flask method
(Albert, 1979). The results obtained were somewhat variable from
day to day. Other workers have found variability in octanol–water
partition coefficients determinations possibly due to the formation
of micelles within the octanol phase of this partition system
(Braumann, 1986; Dearden and Bresnen, 1988). An alternative
method was then developed to measure hydrophobicity (log kw)
using an HPLC system directly coupled to an element-specific
detector (ICP-MS) that detected chloride within the injection
solution to determine the void volume and platinum compounds at
mass 195. The results were more reproducible from day to day but
log kw correlated only weakly with log P, provided a different
hydrophobicity ranking, and predicted the biological distribution
of the compounds less well than log P. It may be that the
chromotographic conditions used were outside the range where
similarities between chromatographic retention, octanol–water
partitioning and membrane permeation have been reported to
occur (Braumann, 1986). Under these conditions log kw proved 
to be an unreliable measure of hydrophobicity of platinum
compounds.
The hydrophobicity of the compounds did correlate, however,
with the concentration of platinum in DRG, sural nerve, sciatic
nerve, spinal cord and brain. The significant inverse correlations
between log P and tissue platinum concentration indicated that
hydrophilic platinum complexes were associated with higher
concentrations of platinum in the peripheral nervous system than
lipophilic platinum complexes. The differential tissue accumula-
tion of hydrophilic and lipophilic platinum complexes was not due
to differences in their absorption after intraperitoneal injection
since there was no correlation between log P and plasma or 
blood platinum concentration. These findings indicate that
hydrophilicity favours the sequestration of platinum in the periph-
eral nervous system, and suggests that the transport of platinum
complexes between the tissue and vascular compartments may
involve hydrophilic transport mechanisms such as paracellular
transport. It would be interesting to extend this observation to
assess whether hydrophilic platinum complexes are preferentially
sequested within tumours as well.
The relative reactivity of cisplatin, carboplatin, JM216 and the
(DACH)Pt complexes with plasma proteins correlated with their
differential peripheral neurotoxicity in the Wistar rat model and in
patients. Differences in reactivity, however, did not account for the
variation in neurotoxicity shown between R,R- and S,S-enan-
tiomers of oxaliplatin and ormaplatin. The relative reactivity of
platinum compounds with plasma proteins depends upon the rate
of formation of aquated reactive electrophilic platinum species
(van der Vijgh and Klein, 1986) that then bind to nucleophilic
sites, on proteins. It may be that the binding of platinum
complexes in, on or outside sensory neurons is involved in the
mechanism of peripheral neurotoxicity.
To conclude, in this study the hydrophilicity of platinum drugs
correlated with their sequestration within the peripheral nervous
system but not with their neurotoxicity. Mechanisms other than the
tissue accumulation of platinum must therefore be involved in
their neurotoxicity. The relative reactivity of the platinum
compounds accounted for some of their differential neurotoxicity.
The effects of the series of platinum drugs on SNCV in a Wistar 
rat model correlated with their neurotoxicity in patients.
Neurotoxicity mechanisms can now be investigated in a validated
experimental model.
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